Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H10N2O4 |
| Molecular Weight | 258.2295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N([C@H]2CCC(=O)NC2=O)C(=O)C3=C1C=CC=C3
InChI
InChIKey=UEJJHQNACJXSKW-VIFPVBQESA-N
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1
| Molecular Formula | C13H10N2O4 |
| Molecular Weight | 258.2295 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: The description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/12175160 | https://www.ncbi.nlm.nih.gov/pubmed/15167912 | https://www.ncbi.nlm.nih.gov/pubmed/19297157
Curator's Comment: The description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/12175160 | https://www.ncbi.nlm.nih.gov/pubmed/15167912 | https://www.ncbi.nlm.nih.gov/pubmed/19297157
(s)-Thalidomide is an enantiomer of immunomodulatory agent Thalidomide. Thalidomide enantiomers are converted to each other in vivo, and Thalidomide contains both left and right-handed isomers in equal amounts. (s)-Thalidomide has proven efficacy in multiple myeloma. s-thalidomide-induced apoptosis associated with increases in I-kB activity, downregulation of NF-kB activity and an increase in Bax: Bcl-2 ratio. In cells cultured with s-thalidomide, there was a four-fold downregulation of the NFkB gene that was associated with a significant decrease in its protein activity.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094258 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | THALOMID Approved UseINDICATIONS AND USAGE.
Thalomid in combination with dexamethasoneisindicated for the treatment of patients with newly diagnosedmultiple myeloma. Thalomid is indicated for the a cute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Launch Date9.003744E11 |
|||
| Primary | THALOMID Approved UseINDICATIONS AND USAGE.
Thalomid in combination with dexamethasoneisindicated for the treatment of patients with newly diagnosedmultiple myeloma. Thalomid is indicated for the a cute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Launch Date9.003744E11 |
Sample Use Guides
Multiple myeloma: 200 mg orally once daily. The recommended dose of
dexamethasone is 40 mg/day on days 1-4, 9-12, and 17-20
every 28 days.
Erythema nodosum leprosum (ENL): 100 to 300 mg/day for an episode of cutaneous ENL.
Up to 400 mg/day for severe cutaneous Erythema nodosum leprosum.
Route of Administration:
Oral
To study the effect of s-thalidomide (Cellgene Corp, NJ, USA) on cell growth, the multiple myeloma cell line U266 was reset in fresh RPMI-1640 culture medium supplemented with s-thalidomide (0–1000 mkM) for 3 days. As s-thalidomide was reconstituted in DMSO, separate cultures of cells with equal amounts of DMSO were also set up as controls. Cell number, cell viability and cell cycle distribution were then assessed on day 3.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:06:16 UTC 2023
by
admin
on
Sat Dec 16 02:06:16 UTC 2023
|
| Record UNII |
TG87FSR590
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
151701
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
92142
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
PRIMARY | |||
|
91730
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
PRIMARY | |||
|
841-67-8
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
PRIMARY | |||
|
61918
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
PRIMARY | |||
|
TG87FSR590
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
PRIMARY | |||
|
DTXSID1046972
Created by
admin on Sat Dec 16 02:06:16 UTC 2023 , Edited by admin on Sat Dec 16 02:06:16 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
